Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology, featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota.
The history of Biocodex started in 1923 with the discovery of the yeast Saccharomyces boulardii CNCM I-745® in Indochina by Henri Boulard. In 1953, Biocodex acquired the rights to Henri Boulard’s yeast strain and fermentation process launching the international pharmaceutical company.
Biocodex USA today
Today, Biocodex has transformed itself, expanding its development around three pillars, microbiota, women’s heath, and orphan drugs. They are represented by 20 different subsidiaries across the globe and over 1,500 employees.
The United States subsidiary has over 50 employees across two business units, Prescription Medicines and Dietary Supplement and Natural Health Products. The Prescription Medicines business unit, based in San Mateo, California, focuses on DIACOMIT® (stiripentol) and the Dietary Supplement and Natural Health business unit, based in Bedminster, New Jersey, focuses on Florastor products.
Want to know more?
With global headquarters in France, Biocodex has expanded its geographic footprint over the past 10 years and today operates through 16 affiliates and long-term partnerships in other countries. Through this international network, Biocodex offers health solutions to patients in more than 100 countries.
Biocodex develops, manufactures and distributes world-class pharmaceutical products and health solutions for patients in more than 120 countries. Focusing on three main pillars (microbiota mission, orphan drugs and women’s health), we combine in house R&D and scientific partnerships, production expertise, and investments in start-ups to remain at the forefront of innovation and quality.